Cargando…

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial

BACKGROUND: Recently, the combination of immunotherapy with chemotherapy has been recommended as first-line treatment of metastatic gastric/gastroesophageal junction (G/GEJ) in the clinical guidelines of many countries; the therapeutic potential of this application needs to be further investigated f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Yuping, Lin, Yao, Yang, Ming, Lv, Jianbo, Liu, Jiaying, Wu, Ke, Liu, Ke, Li, Anshu, Shuai, Xiaoming, Cai, Kailin, Wang, Zheng, Wang, Guobin, Shen, Jianfeng, Zhang, Peng, Tao, Kaixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491115/ https://www.ncbi.nlm.nih.gov/pubmed/36158692 http://dx.doi.org/10.3389/fonc.2022.959295

Ejemplares similares

Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
por: Yen, Chih-Chieh, et al.
Publicado: (2021)

Tegafur/gimeracil/oteracil‐induced eosinophilic pneumonia
por: Sumi, Toshiyuki, et al.
Publicado: (2020)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
por: Zhang, Ximing, et al.
Publicado: (2021)

A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report
por: Liu, Yang-Xi, et al.
Publicado: (2020)

Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer
por: Jiao, Yuyan, et al.
Publicado: (2016)

Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021)

Safety of alternate-day treatment with TS-1(TM) (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study
por: NISHIYAMA, Yuta, et al.
Publicado: (2021)

Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial
por: Wang, Juan, et al.
Publicado: (2020)

Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
por: Qu, Fan-Jie, et al.
Publicado: (2023)

Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin
por: Qi, Jing, et al.
Publicado: (2020)

Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life
por: Liu, Shan, et al.
Publicado: (2021)

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies
por: Kobayakawa, Masao, et al.
Publicado: (2011)

Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
por: Zhang, Wen, et al.
Publicado: (2021)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)
por: Luo, Dongcheng, et al.
Publicado: (2022)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
por: Yang, Jinsong, et al.
Publicado: (2023)

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
por: Lu, Zhihao, et al.
Publicado: (2022)

Tegafur-induced acral hyperpigmentation
por: Teixeira, Vera, et al.
Publicado: (2011)

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
por: Tang, Wen‐Fang, et al.
Publicado: (2021)

Long noncoding RNA metastasis‐associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA‐22/Snail family transcriptional repressor 1 axis
por: Chen, Shaofei, et al.
Publicado: (2020)

Comparative efficacy and tolerability of adjuvant systemic treatments against resectable colon cancer: a network meta-analysis
por: Cheng, Ji, et al.
Publicado: (2020)

Tegafur–Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally Advanced Rectal Cancer
por: Liao, Chun-Kai, et al.
Publicado: (2022)

Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial
por: Abe, Shinya, et al.
Publicado: (2023)

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo
por: Harada, Koji, et al.
Publicado: (2017)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Endoscopic diagnosis and treatment of complete anastomosis stenosis after colorectal resection without protective ileostomy: report of two cases and literature review
por: Deng, Shenghe, et al.
Publicado: (2020)

Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study
por: Liu, Wei, et al.
Publicado: (2022)

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
por: Zhang, Bo, et al.
Publicado: (2022)

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
por: Basso, Valeria, et al.
Publicado: (2019)

EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis
por: Chen, Shaofei, et al.
Publicado: (2018)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

A Cooperative Randomized Study on Tegafur plus Mitomycin C versus Combined Tegafur and Uracil plus Mitomycin C in the Treatment of Advanced Gastric Cancer
por: Kurihara, Minoru, et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_g5kk1qjs69kqnh2idmfo3pujv6